Search | Clinical Trials Finder

Conditions: Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Acupressure Therapy, Best Practice, Biospecimen Collection, Questionnaire Administration; Procedure · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Elevated Triglycerides, Cardiovascular Risk Factor
Interventions: DPA enriched n-3, n-3 control, Placebo; Dietary Supplement
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Depression, Anxiety
Interventions: Growth Mindset and Modifiable Risk Factor Information, Control; Behavioral
Lead sponsor: University of Nevada, Reno; Other
Eligibility: 17 Years to 26 Years
Enrollment: 375 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Bicuspid Aortic Valve Disease, Thoracic Aortic Disease in Patients With a Bicuspid Aortic Valve
Interventions: Not listed
Lead sponsor: Boston University; Other
Eligibility: 8 Years to 90 Years
Enrollment: 6,464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2028
U.S. locations: 5
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Rochester, Minnesota + 1 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: HEPA portable air filter, Sham Control/Active Comparator; Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 40 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Multiple Myeloma
Interventions: ABBV-453, Daratumumab, Dexamethasone, Pomalidomide; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 11
States / cities: Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 8 more

Conditions: HIV Infections, Inpatient Facility Diagnoses
Interventions: Team Based Inpatient ARTAS, Standard of Care; Behavioral
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Shigella
Interventions: ShigETEC vaccine, Placebo, Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU; Biological · Other
Lead sponsor: Eveliqure Biotechnologies GmbH; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Alzheimer Disease
Interventions: Collaborative Dementia Care Program, Screening Only; Behavioral · Other
Lead sponsor: Indiana University; Other
Eligibility: 65 Years and older
Enrollment: 1,822 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Depression, Headaches Chronic, Migraine Disorders
Interventions: CBT Individual Psychotherapy; Behavioral
Lead sponsor: University of Georgia; Other
Eligibility: 18 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Athens, Michigan • Detroit, Michigan

Conditions: Psoriatic Arthritis
Interventions: Deucravacitinib, Placebo, Apremilast; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 24
States / cities: Mountain Brook, Alabama • Sacramento, California • Whittier, California + 21 more

Conditions: Huntington's Disease
Interventions: Placebo, Dimebon; Other · Drug
Lead sponsor: Medivation, Inc.; Industry
Eligibility: 29 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Substance Use Disorders, Mental Illness
Interventions: SBIRT, Health Education; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 1,080 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Los Angeles, California • Oxnard, California

Conditions: Type 2 Diabetes
Interventions: PDA, CDSMP, PDA/CDSMP; Behavioral
Lead sponsor: Scott and White Hospital & Clinic; Other
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Sickle Cell Disease
Interventions: TRF-1101, Placebo; Drug
Lead sponsor: TRF Pharma, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Augusta, Georgia • Chicago, Illinois + 3 more

Conditions: Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy
Interventions: teprotumumab, normal saline; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 11
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more

Conditions: Osteoarthritis, Knee Osteoarthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases
Interventions: Exercise for Knee Osteoarthritis Recommendations (Control group), Exercise for Knee Osteoarthritis -(LBPP supported low-load treadmill Walking), Exercise for Knee Osteoarthritis - (Aquatic Walking); Other
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 50 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Sclerosis, Fatigue, Insomnia
Interventions: Suvorexant, Placebo; Drug
Lead sponsor: Theodore R. Brown, MD MPH; Other
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Kirkland, Washington

Conditions: Lung Cancer, Non Small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: Breathe BioMedical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Orange, California

Conditions: Chronic Kidney Disease, Proteinuria
Interventions: Finerenone (Kerendia, BAY94-8862), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Palo Alto, California • San Diego, California • Hollywood, Florida + 7 more

Conditions: Bulimia Nervosa
Interventions: FBT-BN, SPT; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 12 Years to 19 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sarcoidosis, Berylliosis
Interventions: Not listed
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Bipolar Depression
Interventions: Coenzyme Q10; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 55 Years to 89 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Tezepelumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 337 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 27
States / cities: Dothan, Alabama • Huntington Beach, California • Newport Beach, California + 24 more

Search by objective public record fields.

Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer

Effects of Omega-3 Docosapentaenoic Acid on Lipids and Other Risk Factors for Cardiovascular Disease

Single Session Intervention to Prevent Common Mental Disorders and Among College Students

International Bicuspid Aortic Valve Consortium (BAVCon)

Indoor Air Quality and Respiratory Symptoms in Former Smokers

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Teamwork Makes the Dream Work

Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old

Caregiver Outcomes of Alzheimer's Disease Screening

CBT Depression Intervention for Co-Occurring Chronic Headache

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

A Study of the Novel Drug Dimebon in Patients With Huntington's Disease

Screening, Brief Intervention and Referral to Treatment for Substance Abuse in Mental Health Treatment Settings

Diabetes Self-Management Models to Reduce Health Disparities

TRF-1101 Assessment in Sickle Cell Disease

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

Impact of Different Exercise Programs on Knee OA

A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia

Breath Analysis in Early Stage Lung Cancer Using Infrared Spectroscopy

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

Family Therapy for Adolescent Bulimia Nervosa

Identifying Shared Genetic Susceptibility Regions in Chronic Beryllium Disease and Sarcoidosis

Exploring the Effects of Coenzyme Q10 on Bioenergetics Metabolism in Geriatric Bipolar Depression

Tezepelumab COPD Exacerbation Study